A Study to Determine if an Investigational Pain Medicine Provides Relief of Chronic Pain After a Shingles Outbreak

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether T-62 is effective in providing relief of pain that can occur after an individual experiences a shingles outbreak, which is an infection in adults caused by the same virus that causes chicken pox.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Analgesic Efficacy and Safety Study of T-62 in Subjects With Postherpetic Neuralgia

NCT00809679

Postherpetic Neuralgia

TERMINATED PHASE2

RN624 For Pain Of Post-Herpetic Neuralgia

NCT00568321

Neuralgia, Postherpetic

COMPLETED PHASE2

Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia

NCT01058642

Postherpetic Neuralgia

TERMINATED PHASE2

New Topical Treatment for Continued Pain After Shingles

NCT00566904

Postherpetic Neuralgia

COMPLETED PHASE1

Safety and Preliminary Efficacy of MK0759 in Postherpetic Neuralgia (PHN)(0759-004)

NCT00245544

Neuralgia, Postherpetic

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postherpetic Neuralgia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

T-62

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Has a clinical diagnosis of Postherpetic Neuralgia (PHN)
* Experiencing pain for at least 3 months after the healing of shingles rash
* Has at least a weekly average pain intensity of equal to or greater than 4 out of 10
* Females must not be pregnant or breastfeeding and practicing an acceptable method of birth control, or be surgically sterile or post-menopausal
* Will not consume grapefruit or grapefruit juice during the study

Exclusion Criteria

* Has a current acute or unstable chronic disease other than Postherpetic Neuralgia (PHN)
* Has clinically important medical disorder
* Uses certain types of medications for heart conditions
* Unwilling/unable to discontinue use of medications for treatment of neuropathic pain
* Has a history of hypersensitivity to any medication or soy product
* Has liver or kidney disease
* Has asthma that required treatment within the last year
* Has HIV or hepatitis (other than hepatitis A)
* Has a history of alcohol abuse within the past 2 years
* Has a history of (within last 2 years) or currently abuses prescription or illegal drugs

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No